Agios Pharmaceuticals (AGIO)

$AGIO PROFOUND ..until a LIE comes out of GOFF’s MOUTH Ya know,….similar to TRUMP …but in a BLUE STATE LIES ARE LIES Wherever they are told

$AGIO 💊 1 Hour Levels Price: $28.28 Support: $27.20 Resistance: $29.90 👉 Tap follow to keep these 1-hour levels on your feed.

$AGIO November 19, 2025 …the Promise of the DATA , always telling shareholders it was “ beautiful, never seen anything like it, wonderful “ all adjectives used by a Felon, a con man , and then THE TRUTH ! That day, THE BIG LIE ( like the Big Lie of 2020 ) Senior execs have the TRUMP DIALOGUE, never can deliver.

$AGIO Where is the FDA submission, before QTR 1 of 2026 Another Goff LIE …..same old story here Fouse , Goff and Schenkien , the three musketeers, no leadership , just a milking of the public system of money . None could hold a job in the private sector , since accomplishments are MANDATORY or “ YOU ARE They hold the same con job as this A** Hole

$AGIO Been at this price since Bellevue LLC sold 3.7M shares 11/19/25 …when once again , the misfits LIED So for a quarter ..O % return on investment, but better than since FOUSE ARRIVED in 2018 …and 50% NEAGTIVE RETURN Her reputation from Bunge , followed her here, she gave that form a 50% haircut as well. ( BG) ..look it up !!! she is a born loser , much like TRUMP

$AGIO As stated !!!

$AGIO lol…big message center for a company’s claim they have a submission in the first quarter ….another one of their many lies Misfits still in charge

$AGIO Dog shit

$AGIO 8 years later and 50% lower …. Why ? Senior execs, that are clueless Each one worse than the other !

$AGIO these pathetic senior execs, last calculation, have 20 days to submit their flawed dream of SCD drug . Their exact words were ..” we will submit in the 1st quarter of 2026 “ with the FDA for SCD !!! Now , everyone knows here, THE LIE LIKE TRUMP !

$AGIO @NoelRichards_ ….find another biotech, this ticker is ran by misfits , no scientist left here, just selling insiders and laid off employees of firms that knew they were incompetent. Goff, jones, Fouse, Guehens , Milanova , right down the line 8 years under Fouse , $48 when she arrived …today , lucky to be at $28 , thru her fcuk ups A repeat of her existence ay Bunge (BG) Goff , arrived at $29 …hasn’t done crap for shareholders, since 2022, but sells shares every quarter . A company of losers , on the welfare train of public money

$AGIO biotech with trader interest, if buyers reclaim the range this could trend better

$AGIO lol….another stooge gets beaten by Goff @Gurujoe Hardly a Guru of agios….fools like you rush in to cuddle with biotech’s biggest misfits ..Fouse , Goff , Milanova , Jones , Gehrens …Chris Snowden left …but gave them the pipeline to cash, ty are pissing away with no value created at all

$AGIO Nice puff piece ..but management are imbeciles …always hyping and never deliver

$AGIO – Investor presentation call today: Management was extremely bullish on the strength of their approved mitapivat franchise (PK deficiency + thalassemia) and notably constructive about advancing the drug into sickle cell disease. Tone was confident. It appears the final FDA minutes from the pre-sNDA meeting could arrive within ~30 days — a major catalyst. If FDA supports a BLA submission, the addressable market for mitapivat could more than triple to >$3B peak revenue potential. Importantly, this upside excludes ~$1.2B in cash and does not factor in broader pipeline optionality. Also worth emphasizing: this is an oral therapy in a lifelong disease setting. Current base: • FY25 revenue ~$54M (Q4 ~$20M early launch ramp) • >$1B peak potential already guided in approved indications • Strong balance sheet removes financing risk SCD Phase 3 showed significant hemoglobin improvement and anti-hemolytic activity, though it missed the VOC primary endpoint resulting in a > 50% stock devaluation. The investment debate is now regulatory interpretation, not biology. If FDA allows submission → probability reset event + material TAM expansion. If additional study required → timeline risk, but solvency and franchise durability remain intact. Multiple 2026 pipeline readouts (incl. next-gen PK activators) add optionality. Framing: This is transitioning from a clinical binary to a regulatory probability setup layered on a commercial rare-disease platform. ⚠️ Not investment advice. Personal opinion only. Biotech investing carries substantial risk, including loss of capital. Conduct your own due diligence. Good luck longs!

$BATL $INDO $USEG $TMDE $AGIO Straight of Hormuz officially closed 🚀🚀🚀

$KYMR a true fcuking joke ..almost like a Trump Org !!! Smoke and mirrors and only 1.6B … Hell , the misfits down the street in Cambridge, Ma. At $AGIO , have 1.3B , with drug approvals , but they are misfits and so, $29 ..hahaha and this pos is at $80+ And AGIO, filed for a mixed shelf offering with revenue of 19M a quarter…so, who is blowing who, in the back room of KYMR ??? At AGIO..they just LIE !

Stifel reiterated $FULC Buy/$25 and said it thinks the Market is Splitting Hairs & Misses the Bigger Picture. $CRPR - VRTX $NVO $AGIO $BEAM Oppenheimer reiterated FULC Outperform; $15 PT, and said, We Think FULC Shares are Trading Down Today Because of Profit-Taking. Here's what else Stifel and Oppenheimer had to say: https://x.com/Quantumup1/status/2026332962359263672?s=20

$AGIO another loser , chasing biotech misfits at AGIOS

$AGIO Agios Pharmaceuticals stock, strong close, watch for an upside gap breakout at https://stockconsultant.com/?AGIO

$AGIO good thing you clarified your synopsis. Bellevenue sold out of this pos, after 6 years , 3.9M shares A 40M dollar loss !!!

$AGIO RSI: 64.86, MACD: 0.0838 Vol: 0.73, MA20: 27.87, MA50: 27.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.